Clearside Biomedical, Inc.
CLSD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.15 | 0.67 | 0.00 |
| FCF Yield | -7.59% | -8.26% | -7.91% | -6.28% |
| EV / EBITDA | -32.40 | -23.38 | -22.48 | -25.41 |
| Quality | ||||
| ROIC | -28.17% | -37.92% | -34.52% | -24.79% |
| Gross Margin | 82.93% | 89.36% | 51.31% | 100.00% |
| Cash Conversion Ratio | 0.92 | 1.05 | 0.71 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.62% | 37.06% | 56.39% | 7.84% |
| Free Cash Flow Growth | 18.89% | -2.32% | 4.49% | 2.24% |
| Safety | ||||
| Net Debt / EBITDA | 5.36 | -8.51 | -6.98 | -7.00 |
| Interest Coverage | -1.29 | -1.95 | -2.77 | -2.42 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,060.37 | -635.19 | -727.93 | 68.32 |